Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Advanced Non Small Cell Lung Cancer (NSCLC)~* Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1~* Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment~* Must have at least 1 lesion with measurable disease~Exclusion Criteria:~* Subjects with certain mutations that have not been treated with a targeted therapy prior to enrollment~* Subjects who need daily oxygen therapy~* People with autoimmune disease~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab (Type: ACTIVE_COMPARATOR): Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator
- Nivolumab & Dasatinib (Type: EXPERIMENTAL): Nivolumab in combination with Dasatinib
- Nivolumab & Relatlimab (Type: EXPERIMENTAL): Nivolumab in combination with Relatlimab
- Nivolumab & Ipilimumab (Type: EXPERIMENTAL): Nivolumab in combination with Ipilimumab
- Nivolumab & BMS-986205 (Type: EXPERIMENTAL): Nivolumab in combination with BMS- 986205

Based on this trial design, predict the completion outcome and termination type (if applicable).